Steven Kelly

Vice President

Steve has over 20 years of experience working in health technology assessment, evidence-based medicine, health economics, and pricing and market access within the pharmaceutical industry.

Prior to joining CRA, Steve was Senior Director for Global Health & Value at Pfizer responsible for global market access of hospital products in Pfizer’s established products business. His expertise has focused on pricing and market access in Europe, with in-depth experience of health technology assessment (HTA) in the UK. He has worked on a broad range of therapeutic areas throughout the lifecycle from Phase 2 to post loss of exclusivity.

Selected engagements

  • 01
    Long-term strategic partner in bladder cancer
    We formed a long-term, multi-project partnership with a leading manufacturer that was looking to establish its new product as standard of care in bladder...
    View engagement
  • 02
    Evaluating the potential impact of cross-border healthcare for gene therapies
    CRA's Rare Disease team evaluated the dynamics of cross-border healthcare using secondary research to explore current precedence and/or previous product...
    View engagement
  • 03
    Global pricing and access strategic issues assessment for rare diseases gene therapy portfolio
    CRA delivered recommendations on optimization and risk mitigation for gene therapy pricing strategy implementation...
    View engagement